Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 5.76% is 81% below its 5-year average of 29.75%, near the low end of its 5-year range (-0.87%–89.49%).
58.43% below its 12-month average of 13.86%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.45%.
RETURN ON ASSETS (ROA)
5.76%
RETURN ON ASSETS (ROA) AVG TTM
13.86%
RETURN ON ASSETS (ROA) AVG 3Y
7.25%
RETURN ON ASSETS (ROA) AVG 5Y
29.75%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-58.43%
CURRENT VS 3Y AVG
-20.50%
CURRENT VS 5Y AVG
-80.64%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.12%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
+119.78%
vs the sector median at left
biote Corp.
Market Cap
$50.28M
Return on Assets (ROA)
5.76%
TTM Avg
13.86%
3Y Avg
7.25%
5Y Avg
29.75%
Market Cap
$50.64M
Return on Assets (ROA)
-68.60%
TTM Avg
-124.17%
3Y Avg
-83.59%
5Y Avg
-65.75%
Market Cap
$49.47M
Return on Assets (ROA)
-22.27%
TTM Avg
-102.93%
3Y Avg
-118.23%
5Y Avg
-95.88%
Market Cap
$50.86M
Return on Assets (ROA)
-32404.78%
TTM Avg
-23.59%
3Y Avg
-11.80%
5Y Avg
-9.44%
Market Cap
$51.33M
Return on Assets (ROA)
-97.71%
TTM Avg
-228.91%
3Y Avg
-360.64%
5Y Avg
-295.62%
Market Cap
$49.07M
Return on Assets (ROA)
-171.51%
TTM Avg
-144.24%
3Y Avg
-112.57%
5Y Avg
-82.33%
Market Cap
$51.78M
Return on Assets (ROA)
-162.93%
TTM Avg
-287.06%
3Y Avg
-300.16%
5Y Avg
-220.25%
Market Cap
$51.85M
Return on Assets (ROA)
N/A
TTM Avg
-109.69%
3Y Avg
-346.56%
5Y Avg
-277.44%
Market Cap
$52.31M
Return on Assets (ROA)
-127.67%
TTM Avg
-99.17%
3Y Avg
-76.90%
5Y Avg
-71.83%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| biote Corp. (BTMD) | $50.28M | 5.76% | 13.86% | 7.25% | 29.75% |
| INmune Bio, Inc. (INMB)vs › | $50.64M | -68.60% | -124.17% | -83.59% | -65.75% |
| Microbot Medical Inc. (MBOT)vs › | $49.47M | -22.27% | -102.93% | -118.23% | -95.88% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $50.86M | -32404.78% | -23.59% | -11.80% | -9.44% |
| Envoy Medical, Inc. (COCH)vs › | $51.33M | -97.71% | -228.91% | -360.64% | -295.62% |
| Clene Inc. (CLNN)vs › | $49.07M | -171.51% | -144.24% | -112.57% | -82.33% |
| Apollomics, Inc. (APLM)vs › | $51.78M | -162.93% | -287.06% | -300.16% | -220.25% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.85M | N/A | -109.69% | -346.56% | -277.44% |
| eXoZymes, Inc. (EXOZ)vs › | $52.31M | -127.67% | -99.17% | -76.90% | -71.83% |
| Celularity Inc. (CELU)vs › | $48.05M | -71.66% | -64.58% | -65.51% | -55.75% |
ROA
5.8%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 25.13% |
| 2024-12-31 | 2.58% |
| 2023-12-31 | 2.14% |
| 2022-12-31 | -0.87% |
| 2021-12-31 | 60.04% |
| 2020-12-31 | 89.49% |
| 2019-12-31 | 89.10% |
